Chondrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
- $ 2000
- May 2024
- 116 pages
KEYTRUDA (pembrolizumab) plus chemotherapy as neoadjuvant treatment, then continued as adjuvant monotherapy after surgery for locally advanced, or high-risk early-stage triple-negative breast cancer (TNBC) Pembrolizumab is under development for the treatment of newly diagnosed classical Hodgkin lymphoma, squamous cell carcinoma of paranasal sinus and nasal cavity cancer, metastatic esophageal squamous cell carcinoma, thoracic esophageal squamous cell carcinoma (ESCC), recurrent head and neck cancer squamous cell carcinoma, metastatic pancreatic ductal adenocarcinoma, newly diagnosed high grade glioma, relapsed/refractory acute lymphoblastic leukemia, multiple myeloma (third line therapy), neuroendocrine tumors, metastatic liver cancer, newly diagnosed glioblastoma and gliosarcoma, advanced melanoma, merkel cell carcinoma, metastatic prostate cancer resistant to androgen deprivation, HIV infections, Kaposi sarcoma, head and neck squamous cell carcinoma (adjuvant), adenoid cystic carcinoma, laryngeal squamous cell carcinoma, oropharynx, peripheral nerve sheath tumor, hypopharynx, larynx, oral cavity (mouth) cancer, urethral cancer, ureter cancer, metastatic urothelial bladder cancer, metastatic colorectal cancer, leiomyosarcoma, recurrent meningioma, endometrial, thyroid, anaplastic thyroid cancer, salivary gland cancer, dedifferentiated liposarcoma, synovial sarcoma, Ewing sarcoma, osteosarcoma, chondrosarcoma, soft tissue sarcoma (first line therapy and second line therapy), metastatic renal cell carcinoma, renal cell carcinoma (first line therapy), metastatic gastric cancer, adenocarcinoma of the gastroesophageal junction, esophageal cancer, gastrointestinal stromal tumors, pancreatic cancer, pancreatic ductal adenocarcinoma, metastatic biliary tract cancer, malignant glioma, metastatic/breast cancer, malignant glioma, thymic carcinoma, neuroblastoma, myelodysplastic syndrome, diffuse large B cell lymphoma including primary mediastinal large B cell lymphoma, Richter syndrome, classical Hodgkin lymphoma, basal cell carcinoma, non-Hodgkin lymphoma, non-small cell lung cancer, small- cell lung cancer, B-cell lymphomas, mantle cell lymphoma, chronic lymphocytic leukemia, advanced pleural mesothelioma, primary CNS lymphoma (PCNSL), extranodal diffuse large B-cell lymphoma, gray-zone lymphoma, follicular lymphoma, nongerminomatous (nonseminomatous) germ cell tumors, germinomatous (seminomatous) germ cell tumors, epithelial ovarian, fallopian tube, primary peritoneal carcinoma, non muscle invasive bladder cancer (first line therapy), hepatocellular carcinoma (as first line and second line therapy),metastatic adenocarcinoma of the pancreas, small intestine cancer, gliosarcoma, anal cancer, mycosis fungoides, sezary syndrome, leptomeningeal carcinomatosis, chronic phase myelofibrosis, polycythemia vera, post-essential thrombocythemia myelofibrosis and primary myelofibrosis.